Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 5/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594188 | 0.91 | — | — | |
| SCHEMBL594189 | 0.91 | — | — | |
| SCHEMBL4259672 | 0.91 | — | — | |
| Isoleucine SCHEMBL31276087 | 0.83 | SLC7A5 (0.46) | SLC7A5LAP3METAP1 | |
| SCHEMBL417728 | 0.78 | SLC7A5 (0.46) | SLC7A5LAP3ANPEPMETAP1 | |
| SCHEMBL462556 | 0.78 | SLC7A5 (0.46) | SLC7A5LAP3ANPEPMETAP1 | |
| SCHEMBL28890361 | 0.78 | USP2 (0.57) | SLC7A5USP2SLCO1B1LAP3 | |
| Threonine SCHEMBL15571793 | 0.78 | USP2 (0.42) | SLC7A5USP2SLCO1B1LAP3ANPEP | |
| Valine SCHEMBL1758768 | 0.77 | SLC7A5 (0.79) | SLC7A5LAP3ANPEP | |
| Valine SCHEMBL16010343 | 0.77 | SLC7A5 (0.79) | SLC7A5LAP3ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650417-B2 | Treatments for gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-20160213739-A1 | TREATMENTS FOR DISORDERS USING GUANYLATE CYCLASE C AGONISTS | IRONWOOD PHARMACEUTICALS, INC (US) | 2016-07-28 | — | — | US | claimed |
| US-9303066-B2 | Treatments for gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | claimed |
| WO-2016015055-A1 | COLON CLEANSING COMPOSITIONS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | claimed |
| US-8946158-B2 | Treatments of gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20150030697-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | claimed |
| US-20140323397-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | claimed |
| US-20140179607-A9 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | claimed |
| US-20140024593-A1 | Treatments of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | claimed |
| US-8507447-B2 | Treatments for gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20130085107-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC (US) | 2013-04-04 | — | — | US | claimed |
| WO-2012155114-A1 | PEPTIDES DERIVED FROM UROGUANYLIN AND THEIR USE IN GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| WO-2012155108-A1 | TREATMENTS FOR DISORDERS USING GUANYLATE CYCLASE C AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| WO-2012155101-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| EP-2499154-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2012-09-19 | — | — | EP | claimed |
| US-20110118184-A1 | Treatments of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| WO-2011057272-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-9650417-B2 | Treatments for gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20110118184-A1 | Treatments of Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011057272-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030697-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | SLC10A2, SI, FABP2 | SLC7A5 1770/4885USP2 1645/4885SLCO1B1 1363/4885 |
| US-20140179607-A9 | Treatments for Gastrointestinal Disorders | VIP, GIPR, GRPR | SLC7A5 2190/4885USP2 2811/4885SLCO1B1 1661/4885 |
| US-20140024593-A1 | Treatments of Gastrointestinal Disorders | VIP, GIPR, GRPR | SLC7A5 2175/4885USP2 2865/4885SLCO1B1 1526/4885 |
| US-20130085107-A1 | Treatments for Gastrointestinal Disorders | VIP, GIPR, GRPR | SLC7A5 2190/4885USP2 2811/4885SLCO1B1 1661/4885 |
| US-20160213739-A1 | TREATMENTS FOR DISORDERS USING GUANYLATE CYCLASE C AGONISTS | GMPS, GUCY1A1, PDE3B | SLC7A5 2768/4885USP2 4147/4885SLCO1B1 2683/4885 |
| US-20140323397-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | VIP, FABP6, PLAU | SLC7A5 4031/4885USP2 1023/4885SLCO1B1 2634/4885 |
| US-20110118184-A1 | Treatments of Gastrointestinal Disorders | VIP, GIPR, GRPR | SLC7A5 2175/4885USP2 2865/4885SLCO1B1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.